Drug Type Antibody fusion proteins |
Synonyms- |
Target |
Action stimulants, inhibitors |
Mechanism IL-12 stimulants(Interleukin-12 stimulants), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain Cancer | Preclinical | Switzerland | 01 Oct 2020 |